Dendreon Corp (DNDN.OQ)
3.92USD
12:47pm EDT
$-0.09 (-2.24%)
$4.01
$4.01
$4.01
$3.91
508,194
902,715
$7.94
$3.69
DNDN.OQ
About
Overall
| Beta: | 3.77 |
| Market Cap (Mil.): | $631.98 |
| Shares Outstanding (Mil.): | 157.60 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| DNDN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 53.78 | 35.83 |
| EPS (TTM): | -2.42 | -- | -- |
| ROI: | -51.38 | 1.00 | 18.72 |
| ROE: | -296.94 | 2.10 | 19.54 |
Dendreon's cancer vaccine sales drop as competition heats up
- Sales of Dendreon Corp's prostate cancer vaccine Provenge declined in the first quarter despite efforts by the biotechnology drugs maker to shore up flagging volumes.
UPDATE 2-Dendreon's cancer vaccine sales drop as competition heats up
* Co says competition, lack of patient access caused sales decline
Analyst says Dendreon recommendation "worst" of career, apologizes
- Wall Street analysts aren't known to apologize for giving bad advice on stocks, much less admit they've made the worst call of their entire careers.
Dendreon posts smaller-than-expected quarterly loss
- Dendreon Corp reported a smaller-than-expected quarterly loss versus a year-ago profit on Monday as revenue fell and restructuring costs weighed on the biotechnology company.
UPDATE 2-Dendreon posts smaller-than-expected quarterly loss
Feb 25 - Dendreon Corp reported a smaller-than-expected quarterly loss versus a year-ago profit on Monday as revenue fell and restructuring costs weighed on the biotechnology company.
Dendreon posts fourth-quarter loss versus year-ago profit
- Dendreon Corp reported a quarterly loss versus a year-ago profit on Monday as revenue fell and restructuring costs weighed on the biotechnology company.
Dendreon posts 4th-quarter loss versus year-ago profit
Feb 25 - Dendreon Corp reported a quarterly loss versus a year-ago profit on Monday as revenue fell and restructuring costs weighed on the biotechnology company.
Bernstein upgrades Dendreon to outperform, shares jump
- Sanford C. Bernstein upgraded Dendreon Corp to "outperform" from "market-perform" and said the drugmaker could be one of the best performers in 2013, sending its shares up 15 percent before the bell.
BRIEF-Dendreon shares jump in premarket
NEW YORK, Jan 11 - Dendreon Corp : * Shares jump 12.4 percent to $5.73 in premarket
Competitors
| Price | Change | |
|---|---|---|
| Medivation Inc (MDVN.OQ) | $47.73 | +0.20 |
| Pfizer Inc. (PFE.N) | $28.91 | -0.05 |
| Johnson & Johnson (JNJ.N) | $88.09 | 0.00 |
| Novartis AG (NOVN.VX) | CHF71.75 | -0.45 |
| Abbott Laboratories (ABT.N) | $37.81 | +1.22 |
| Eli Lilly & Co. (LLY.N) | $55.49 | -0.41 |
| Bristol Myers Squibb Co. (BMY.N) | $43.73 | +0.43 |
| Bristol Myers Squibb Co. (BMY_p.N) | $567.60 | 0.00 |
| Amgen, Inc. (AMGN.OQ) | $102.30 | -3.33 |
| Mylan Inc. (MYL.OQ) | $31.38 | -0.02 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: S&P Capital IQ Factual Report
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
